Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aura Biosciences (AURA) Total Liabilities (2020 - 2026)

Aura Biosciences filings provide 7 years of Total Liabilities readings, the most recent being $30.4 million for Q1 2026.

  • Quarterly Total Liabilities rose 10.92% to $30.4 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $30.4 million through Mar 2026, up 10.92% year-over-year, with the annual reading at $32.5 million for FY2025, 6.5% up from the prior year.
  • Total Liabilities hit $30.4 million in Q1 2026 for Aura Biosciences, down from $32.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $33.4 million in Q3 2025 and bottomed at $5.3 million in Q1 2022.
  • Average Total Liabilities over 5 years is $26.2 million, with a median of $28.1 million recorded in 2022.
  • The largest annual shift saw Total Liabilities plummeted 95.33% in 2022 before it surged 382.78% in 2023.
  • Aura Biosciences' Total Liabilities stood at $28.4 million in 2022, then grew by 3.09% to $29.2 million in 2023, then rose by 4.47% to $30.5 million in 2024, then grew by 6.5% to $32.5 million in 2025, then decreased by 6.42% to $30.4 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Total Liabilities are $30.4 million (Q1 2026), $32.5 million (Q4 2025), and $33.4 million (Q3 2025).